Robert L. Dobbins

10.1k citations

60 papers · 8.0k indexed · 3 hit papers · h-index 30

Epidemiology top 0.2%
Endocrinology, Diabetes and Metabolism top 0.2%
Molecular Biology top 5%
Physiology top 1%
Surgery top 2%

Co-authors: Lidia S. Szczepaniak Helen H. Hobbs Jeffrey D. Browning Scott M. Grundy Julie McGarry Jay D. Horton Jonathan C. Cohen Pamela Nurenberg
Topics: Diabetes Treatment and Management (22 papers)Diabetes Management and Research (15 papers)Pancreatic function and diabetes (15 papers)
Cited by: Endocrinology, Diabetes and Metabolism Hepatology Epidemiology
Journals: The Lancet Journal of Clinical Investigation Gastroenterology
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Robert L. Dobbins

58 papers receiving 7.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

2004 2.9k citations Lidia S. Szczepaniak, Robert L. Dobbins et al. profile →
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

2004 1.2k citations Lidia S. Szczepaniak, Robert L. Dobbins et al. profile →
Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo

1999 583 citations Lidia S. Szczepaniak, Robert L. Dobbins et al. profile →

Peers

Countries citing papers authored by Robert L. Dobbins

Since Specialization

Citations

This map shows the geographic impact of Robert L. Dobbins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert L. Dobbins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert L. Dobbins more than expected).

Fields of papers citing papers by Robert L. Dobbins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert L. Dobbins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert L. Dobbins. The network helps show where Robert L. Dobbins may publish in the future.

Co-authorship network of co-authors of Robert L. Dobbins

This figure shows the co-authorship network connecting the top 25 collaborators of Robert L. Dobbins. A scholar is included among the top collaborators of Robert L. Dobbins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert L. Dobbins. Robert L. Dobbins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine 2025 ·JAMA Network Open ·Rajinder Shiwach,Bernard Le Foll,Hannu Alho,Kelly E. Dunn,(unknown),Yue Zhao,Robert L. Dobbins	2
2	Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use 2025 ·JAMA Network Open ·Rajinder Shiwach,Bernard Le Foll,Hannu Alho,Kelly E. Dunn,(unknown),Yue Zhao,Robert L. Dobbins	0
3	A Single‐Dose Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Monthly Extended-Release Buprenorphine at Alternative Injection Locations in Adult Participants with Opioid Use Disorder 2024 ·Clinical Drug Investigation ·Céline M. Laffont,(unknown),Dipti Mangal,Robert L. Dobbins	3
4	Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs 2023 ·American Journal on Addictions ·John J. Mariani,Robert L. Dobbins,Amy Heath,(unknown),(unknown)	8
5	Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients 2022 ·PLoS ONE ·(unknown),(unknown),Robert L. Dobbins,(unknown),(unknown),Amy Heath,Monique van Velzen,Jules A. A. C. Heuberger,Marieke Niesters,Erik Olofsen,Céline M. Laffont,Albert Dahan,Geert Jan Groeneveld	25
6	Modeling buprenorphine reduction of fentanyl-induced respiratory depression 2022 ·JCI Insight ·Erik Olofsen,(unknown),(unknown),Robert L. Dobbins,Geert Jan Groeneveld,Monique van Velzen,Marieke Niesters,Albert Dahan,Céline M. Laffont	21
7	Tolerance to Opioid‐Induced Respiratory Depression in Chronic High‐Dose Opioid Users: A Model‐Based Comparison With Opioid‐Naïve Individuals 2020 ·Clinical Pharmacology & Therapeutics ·(unknown),Erik Olofsen,(unknown),Robert L. Dobbins,Marieke Niesters,Monique van Velzen,Geert Jan Groeneveld,Jules A. A. C. Heuberger,Céline M. Laffont,Albert Dahan	39
8	Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study 2017 ·The Lancet ·Vinod S. Hegade,Stuart Kendrick,Robert L. Dobbins,Sam R. Miller,Douglas Thompson,Duncan Richards,James R. Storey,George E. Dukes,Margaret Corrigan,Ronald P.J. Oude Elferink,Ulrich Beuers,Gideon M. Hirschfield,David E.J. Jones	162
9	BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial 2016 ·BMC Gastroenterology ·Vinod S. Hegade,Stuart Kendrick,Robert L. Dobbins,Sam R. Miller,Duncan Richards,James R. Storey,George E. Dukes,Kim Gilchrist,Susan Vallow,Graeme Alexander,Margaret Corrigan,Gideon M. Hirschfield,David Jones	33
10	Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes 2014 ·Diabetes Obesity and Metabolism ·A.P. Sykes,(unknown),Robert L. Dobbins,(unknown),(unknown),W. O. Wilkison,Susan Walker,Lata Kler	28
11	Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long‐acting glucagon‐like peptide‐1 mimetic, in healthy subjects 2009 ·Diabetes Obesity and Metabolism ·Mark Bush,Jessica Matthews,Erika H. De Boever,Robert L. Dobbins,Rebecca J. Hodge,Susan Walker,M. Claire Holland,(unknown),Murray Stewart	143
12	Proton and sodium MRI assessment of fluid level in calf tissue 2006 ·Journal of Magnetic Resonance Imaging ·Chun S. Zuo,Rosemond A. Villafuerte,Michael Henry,(unknown),Robert L. Dobbins,(unknown),(unknown),(unknown),Liqun Wang,Andy Brown,Derek J. Nunez,John Brown,Perry F. Renshaw	3
13	Myocardial triglycerides and systolic function in humans: In vivo evaluation by localized proton spectroscopy and cardiac imaging 2003 ·Magnetic Resonance in Medicine ·Lidia S. Szczepaniak,Robert L. Dobbins,Gregory J. Metzger,(unknown),Debbie Arbique,Wanpen Vongpatanasin,Roger H. Unger,Ronald G. Victor	349
14	Knockout Mice Lacking Steroidogenic Factor 1 Are a Novel Genetic Model of Hypothalamic Obesity 2002 ·Endocrinology ·Gregor Majdič,Morag J. Young,Elise P. Gómez-Sánchez,Paul Anderson,Lidia S. Szczepaniak,Robert L. Dobbins,Julie McGarry,Keith L. Parker	228
15	Bulk magnetic susceptibility effects on the assessment of intra‐ and extramyocellular lipids in vivo 2002 ·Magnetic Resonance in Medicine ·Lidia S. Szczepaniak,Robert L. Dobbins,Daniel T. Stein,Julie McGarry	63
16	Fatty acids, lipotoxicity and insulin secretion 1999 ·Diabetologia ·Julie McGarry,Robert L. Dobbins	445
17	Rates of glucagon activation and deactivation of hepatic glucose production in conscious dogs 1998 ·Metabolism ·Robert L. Dobbins,Stephen N. Davis,Doss W. Neal,Andrea Caumo,Claudio Cobelli,Alan D. Cherrington	11
18	A fatty acid- dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion. 1998 ·Journal of Clinical Investigation ·Robert L. Dobbins,M Chester,(unknown),(unknown),Daniel T. Stein,Julie McGarry	123
19	Counterregulation by epinephrine and glucagon during insulin-induced hypoglycemia in the conscious dog 1996 ·Diabetes Research and Clinical Practice ·(unknown),(unknown),(unknown),Robert L. Dobbins,Doss W. Neal,Phillip E. Williams,Alan D. Cherrington	11
20	Evidence that the brain of the conscious dog is insulin sensitive. 1995 ·Journal of Clinical Investigation ·Stephen N. Davis,(unknown),Robert L. Dobbins,Stephen E. Nadeau,Doss W. Neal,Phillip Williams,Alan D. Cherrington	53

About Robert L. Dobbins

Robert L. Dobbins is a scholar working on Endocrinology, Diabetes and Metabolism, Endocrine and Autonomic Systems and Anesthesiology and Pain Medicine, having authored 60 papers that have together received 8.0k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (22 papers), Diabetes Management and Research (15 papers) and Pancreatic function and diabetes (15 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (3.3k citations), Hepatology (1.6k citations) and Epidemiology (4.4k citations). Robert L. Dobbins has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Lidia S. Szczepaniak, Helen H. Hobbs, Jeffrey D. Browning, Scott M. Grundy, Julie McGarry, Jay D. Horton, Jonathan C. Cohen, Pamela Nurenberg, David Léonard and Jason Reingold. Their work appears in journals such as The Lancet, Journal of Clinical Investigation and Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact